Pronethalol
A non-selective beta blocker
| Pronethalol | |
|---|---|
| |
| INN | |
| Drug class | |
| Routes of administration | |
| Pregnancy category | |
| Bioavailability | |
| Metabolism | |
| Elimination half-life | |
| Excretion | |
| Legal status | |
| CAS Number | |
| PubChem | |
| DrugBank | |
| ChemSpider | |
| KEGG | |
Pronethalol is a non-selective beta blocker that was developed in the early 1960s. It was one of the first beta blockers to be synthesized and was used in the treatment of angina pectoris and hypertension. However, it was later withdrawn from the market due to concerns about its safety profile.
History[edit | edit source]
Pronethalol was developed by Imperial Chemical Industries (ICI) in the early 1960s. It was part of the pioneering work on beta blockers by Sir James Black, who later received the Nobel Prize in Physiology or Medicine for his contributions to the development of beta blockers and H2 receptor antagonists.
Mechanism of Action[edit | edit source]
Pronethalol works by blocking beta-adrenergic receptors, which are part of the sympathetic nervous system. By inhibiting these receptors, pronethalol reduces the effects of adrenaline and noradrenaline, leading to a decrease in heart rate and blood pressure. This makes it useful in the management of conditions like angina and hypertension.
Clinical Use[edit | edit source]
Initially, pronethalol was used to treat angina pectoris, a condition characterized by chest pain due to reduced blood flow to the heart. It was also used to manage hypertension, or high blood pressure. However, its use was limited due to the discovery of more effective and safer beta blockers.
Safety Concerns[edit | edit source]
Pronethalol was withdrawn from the market after studies indicated that it could cause carcinogenic effects in laboratory animals. This led to the development and use of other beta blockers, such as propranolol, which had a better safety profile.
Legacy[edit | edit source]
Despite its withdrawal, pronethalol played a crucial role in the development of beta blockers. It paved the way for the synthesis of safer and more effective beta blockers that are widely used today in the treatment of cardiovascular diseases.
Related pages[edit | edit source]
Pronethalol
Search WikiMD
Ad.Tired of being Overweight? Try W8MD's physician weight loss program.
Semaglutide (Ozempic / Wegovy and Tirzepatide (Mounjaro / Zepbound) available.
Advertise on WikiMD
|
WikiMD's Wellness Encyclopedia |
| Let Food Be Thy Medicine Medicine Thy Food - Hippocrates |
Translate this page: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
தமிழ்,
తెలుగు,
Urdu,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
বাংলা
European
español,
Deutsch,
français,
Greek,
português do Brasil,
polski,
română,
русский,
Nederlands,
norsk,
svenska,
suomi,
Italian
Middle Eastern & African
عربى,
Turkish,
Persian,
Hebrew,
Afrikaans,
isiZulu,
Kiswahili,
Other
Bulgarian,
Hungarian,
Czech,
Swedish,
മലയാളം,
मराठी,
ਪੰਜਾਬੀ,
ગુજરાતી,
Portuguese,
Ukrainian
Medical Disclaimer: WikiMD is not a substitute for professional medical advice. The information on WikiMD is provided as an information resource only, may be incorrect, outdated or misleading, and is not to be used or relied on for any diagnostic or treatment purposes. Please consult your health care provider before making any healthcare decisions or for guidance about a specific medical condition. WikiMD expressly disclaims responsibility, and shall have no liability, for any damages, loss, injury, or liability whatsoever suffered as a result of your reliance on the information contained in this site. By visiting this site you agree to the foregoing terms and conditions, which may from time to time be changed or supplemented by WikiMD. If you do not agree to the foregoing terms and conditions, you should not enter or use this site. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates, categories Wikipedia, licensed under CC BY SA or similar.
Contributors: Prab R. Tumpati, MD
